This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
New York-based Bristol-Myers Squibb is a one of the leading global specialty bio-pharmaceutical companies focused on the development of treatments targeting serious diseases. Backed by its blockbuster immune-oncology drug, Opdivo, Bristol-Myers has a strong oncology portfolio, consisting of other drugs like Revlimid, Sprycel, Yervoy and Empliciti. Beyond oncology, the company has important immunology and cardiovascular drugs like Orencia and Eliquis, which diversify its portfolio. Notably, in the cardiovascular space, Eliquis is now the global leading oral anti-coagulant drug. The company continues to experience growth in both the Eliquis brand and the market, while also advancing its Factor XIa inhibitor program..
The Zacks Analyst Blog Highlights Apple, Alibaba, Bristol-Myers Squibb, Tesla and Cigna
by Zacks Equity Research
Apple, Alibaba, Bristol-Myers Squibb, Tesla and Cigna are part of The Zacks top Analyst Blog.
Top Analyst Reports for Apple, Alibaba & Bristol-Myers Squibb
by Mark Vickery
Today's Research Daily features new research reports on 12 major stocks, including Apple Inc. (AAPL), Alibaba Group Holding Limited (BABA) and Bristol-Myers Squibb Company (BMY).
Iovance (IOVA) Starts Rolling BLA With FDA for Melanoma Therapy
by Zacks Equity Research
Iovance (IOVA) starts a rolling BLA submission with the FDA seeking approval for its lead pipeline candidate in advanced melanoma patients. The filing is expected to be completed by fourth-quarter 2022.
Bristol Myers (BMY) Up 14.6% YTD: Will the Performance Continue?
by Zacks Equity Research
Bristol Myers (BMY) has put up an impressive performance so far in 2022, and the momentum should continue on label expansion of existing drugs.
Should SPDR Portfolio S&P 500 High Dividend ETF (SPYD) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for SPYD
bluebird bio (BLUE) Focused on Pipeline Amid Marketed Drug Dearth
by Zacks Equity Research
bluebird bio's (BLUE) efforts to develop its gene-therapy pipeline are impressive. The FDA is reviewing BLUE's filing for beti-cel as a treatment for beta thalassemia and eli-cel for cerebral adrenoleukodystrophy.
Should You Invest in the VanEck Pharmaceutical ETF (PPH)?
by Zacks Equity Research
Sector ETF report for PPH
Bristol Myers (BMY) Posts Data From Multiple Myeloma Study
by Zacks Equity Research
Bristol Myers (BMY) and partner, 2seventy bio, report top-line data from a late-stage study evaluating Abecma for multiple myeloma patients after two or more lines of prior therapy.
Exelixis (EXEL) Q2 Earnings Beat, Cabometyx Maintains Growth
by Zacks Equity Research
Exelixis (EXEL) tops earnings and sales in the second quarter as lead drug Cabometyx maintains momentum.
Prothena (PRTA) Q2 Earnings Miss, Pipeline Progress in Focus
by Zacks Equity Research
Prothena (PRTA) incurs a loss in the second quarter while revenues miss estimates.
Clovis (CLVS) Q2 Loss Wider Than Expected, Revenues Miss
by Zacks Equity Research
Clovis (CLVS) incurs a wider-than-estimated loss in second-quarter 2022. Sales of the sole marketed drug Rubraca decline year over year due to COVID-19 impacts. CLVS faces the risk of a cash crunch.
Iovance (IOVA) Q2 Earnings Miss, Lifileucel BLA on Track
by Zacks Equity Research
Iovance Biotherapeutics (IOVA) reports a wider-than-expected second-quarter loss. The company is on track to initiate a rolling BLA submission for lifileucel in melanoma later this month.
Nektar's (NKTR) Q2 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Nektar (NKTR) reports dismal second-quarter 2022 results. The company's operating expenses increased due to restructuring expenses of $106.0 million incurred during the quarter.
Mirati (MRTX) Q2 Loss Narrower Than Expected, Sales Beat
by Zacks Equity Research
Mirati Therapeutics' (MRTX) Q2 earnings and sales beat the mark. The company plans to start early-stage clinical studies for a SOS1 inhibitor by year-end.
Is SPDR Portfolio S&P 500 High Dividend ETF (SPYD) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for SPYD
Pfizer (PFE) Q2 Earnings Top, COVID Products Drive Sales
by Zacks Equity Research
Pfizer (PFE) beats estimates for Q2 earnings and sales. It maintains the sales forecast for COVID products, Comirnaty and Paxlovid.
Biotech Stock Roundup: BMY, BIIB's Q2 Earnings, GILD's Updates & More
by Zacks Equity Research
Earnings updates from Bristol Myers (BMY) and Biogen (BIIB) are a few key highlights from the biotech sector during the past week.
Bristol-Myers (BMY) Q2 Earnings, Sales Beat on Eliquis, Opdivo
by Zacks Equity Research
Bristol-Myers (BMY) earnings and sales beat estimates in the second quarter of 2022 on the back of Eliquis and Opdivo and a lesser decline in sales of Revlimid.
TEVA Beats on Q2 Earnings, to Settle Opioid Lawsuit for $4.3B
by Zacks Equity Research
TEVA reports mixed Q2 results. It lowers its sales expectations for 2022 while keeping the adjusted earnings per share guidance intact. The company agrees to settle opioid lawsuits for as much as $4.25 billion.
Bristol Myers Squibb (BMY) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Bristol Myers (BMY) delivered earnings and revenue surprises of 7.82% and 3.72%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Q2 Earnings Season Scorecard and Analyst Reports for Broadcom, Oracle, & Danaher
by Sheraz Mian
Today's Research Daily features a real-time update on the Q2 earnings season and new research reports on Broadcom (AVGO), Oracle (ORCL), and Danaher (DHR).
Drug, Biotech Stocks' Q2 Earnings on Jul 27: BMY, GSK & More
by Zacks Equity Research
Let's look what is in store for the four drug, biotech companies slated to release quarterly results tomorrow- BMY, GSK, ALKS, TEVA
Bristol-Myers (BMY) to Post Q2 Earnings: What is in the Cards?
by Zacks Equity Research
Investors will likely focus on the demand for Eliquis and Opdivo along with incremental contribution from newer drugs when Bristol-Myers (BMY) reports Q2 results. Operating expenses might have jumped.
Healthcare ETFs in Focus Ahead of Q2 Earnings
by Sweta Killa
The healthcare sector has gained some momentum lately on investors' rush to safety in a volatile stock market. The sector is non-cyclical in nature, which in turn, is providing a cushion to the portfolio.
Earnings Preview: Bristol Myers Squibb (BMY) Q2 Earnings Expected to Decline
by Zacks Equity Research
Bristol Myers (BMY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.